PMID- 36618419
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20230119
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping 
      review.
PG  - 1103020
LID - 10.3389/fimmu.2022.1103020 [doi]
LID - 1103020
AB  - BACKGROUND: COVID-19 vaccines are required for individuals with myasthenia gravis 
      (MG), as these patients are more likely to experience severe pneumonia, 
      myasthenia crises, and higher mortality rate. However, direct data on the safety 
      of COVID-19 vaccines in patients with MG are lacking, which results in hesitation 
      in vaccination. This scoping was conducted to collect and summarize the existing 
      evidence on this issue. METHODS: PubMed, Cochrane Library, and Web of Science 
      were searched for studies using inclusion and exclusion criteria. Article titles, 
      authors, study designs, demographics of patients, vaccination information, 
      adverse events (AEs), significant findings, and conclusions of included studies 
      were recorded and summarized. RESULTS: Twenty-nine studies conducted in 16 
      different countries in 2021 and 2022 were included. Study designs included case 
      report, case series, cohort study, cross-sectional study, survey-based study, 
      chart review, and systemic review. A total of 1347 patients were included. The 
      vaccines used included BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, inactivated 
      vaccines, and recombinant subunit vaccines. Fifteen case studies included 48 
      patients reported that 23 experienced new-onset, and five patients experienced 
      flare of symptoms. Eleven other types of studies included 1299 patients reported 
      that nine patients experienced new-onset, and 60 participants experienced flare 
      of symptoms. Common AEs included local pain, fatigue, asthenia, cephalalgia, 
      fever, and myalgia. Most patients responded well to treatment without severe 
      sequelae. Evidence gaps include limited strength of study designs, type and dose 
      of vaccines varied, inconsistent window of risk and exacerbation criteria, 
      limited number of participants, and lack of efficacy evaluation. CONCLUSION: 
      COVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of 
      population. Large-scale, multicenter, prospective, and rigorous studies are 
      required to verify their safety.
CI  - Copyright (c) 2022 Peng, Tian, Meng, Fang, Chang, Yang, Li, Shen, Ni and Zhu.
FAU - Peng, Siyang
AU  - Peng S
AD  - Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Tian, Yukun
AU  - Tian Y
AD  - Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Meng, Linghao
AU  - Meng L
AD  - Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Fang, Ruiying
AU  - Fang R
AD  - Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Chang, Weiqian
AU  - Chang W
AD  - Department of Acupuncture, Guang'anmen Hospital, Chinese Academy of Traditional 
      Chinese Medicine Ji'nan Hospital (Ji'nan Hospital of Traditional Chinese 
      Medicine), Shandong, China.
FAU - Yang, Yajing
AU  - Yang Y
AD  - Department of Traditional Chinese Medicine, Yuyuantan Community Health Center, 
      Beijing, China.
FAU - Li, Shaohong
AU  - Li S
AD  - Treatment Center of Traditional Chinese Medicine, Beijing Bo'ai Hospital, China 
      Rehabilitation Research Center, Beijing, China.
AD  - Treatment Center of Traditional Chinese Medicine, School of Rehabilitation, 
      Capital Medical University, Beijing, China.
FAU - Shen, Qiqi
AU  - Shen Q
AD  - Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Ni, Jinxia
AU  - Ni J
AD  - Department of Acupuncture, Dongzhimen Hospital of Beijing University of 
      Traditional Chinese Medicine, Beijing, China.
FAU - Zhu, Wenzeng
AU  - Zhu W
AD  - Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221222
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (BNT162 Vaccine)
RN  - B5S3K2V0G8 (ChAdOx1 nCoV-19)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Vaccines, Inactivated)
SB  - IM
MH  - Humans
MH  - BNT162 Vaccine
MH  - ChAdOx1 nCoV-19
MH  - Cohort Studies
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Cross-Sectional Studies
MH  - Multicenter Studies as Topic
MH  - *Myasthenia Gravis
MH  - Prospective Studies
MH  - Vaccines, Inactivated
PMC - PMC9812949
OTO - NOTNLM
OT  - COVID-19
OT  - SARS-CoV-2
OT  - myasthenia gravis
OT  - safety
OT  - vaccines
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/10 06:00
MHDA- 2023/01/11 06:00
PMCR- 2022/12/22
CRDT- 2023/01/09 03:31
PHST- 2022/11/19 00:00 [received]
PHST- 2022/12/06 00:00 [accepted]
PHST- 2023/01/09 03:31 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/12/22 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1103020 [doi]
PST - epublish
SO  - Front Immunol. 2022 Dec 22;13:1103020. doi: 10.3389/fimmu.2022.1103020. 
      eCollection 2022.